CORIE MOUSSIGNAC-DEVILME: Open Payments
NPI 1720703945 · LAWRENCEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,886 in 73 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $334 · 2025 $1,886
Food & beverage: $1,886
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $529 |
| Madrigal Pharmaceuticals | 8 | $331 |
| Janssen Biotech, Inc. | 7 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $179 |
| Novo Nordisk Inc | 2 | $150 |
| PFIZER INC. | 4 | $112 |
| GENZYME CORPORATION | 3 | $75 |
| Gilead Sciences, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $42 |
| Braintree Laboratories, Inc. | 2 | $37 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, SKYRIZI, Wegovy, ENTYVIO, LINZESS, CREON.
Industry payments across GA — which companies pay providers there.
